Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€99.92

€99.92

-0.250%
-0.25
-0.250%
€115.00
 
26.04.24 / Tradegate WKN: SYM999 / Name: Symrise / Stock / Chemicals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Symrise AG Stock

Symrise AG shows a slight decrease today, losing -€0.250 (-0.250%) compared to yesterday.
Our community is currently high on Symrise AG with 3 Buy predictions and 0 Sell predictions.
With a target price of 115 € there is a slightly positive potential of 15.09% for Symrise AG compared to the current price of 99.92 €.
So far the community has only identified positive things for Symrise AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Symrise AG in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Symrise AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Symrise AG -0.250% -5.109% -9.164% -7.138% 0.301% -9.287% 18.642%
Henkel AG & Co. KGaA VZO 1.160% 1.413% -1.001% 0.412% 0.632% -23.415% -17.307%
Henkel AG & Co. KGaA ST 0.530% 1.139% -0.210% -0.210% 2.588% -19.517% -20.240%
Covestro AG 0.460% -0.702% -3.335% 30.805% -8.986% -14.334% -5.667%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-20

The general impression of Symrise's financials seems to be quite positive, showing a company that has managed to grow its assets, revenues, and profitability over the years. The consistent increase in financials is a positive sign for any investor interested in the company. However, a deeper dive into the balance sheets, cash flows, and income statements can provide a more nuanced view of the pros and cons of this company in the chemical industry.

*Pros: *

Asset Growth: Over the years, Symrise's balance sheet has shown a noticeable growth in assets. In 2020, the company's total assets were around €5.93 billion, which increased to €6.64 billion in 2021 and €7.78 billion in 2022. This growth indicates that the company has managed to expand its operations, either through acquisitions or organic growth.

Comments

Buy Symrise AG Inh.
Show more

Buy Symrise AG Inh.
Show more

Buy Symrise AG Inh.
Show more

News

EQS-News: Symrise sees successful start into the 2024 fiscal year: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23742/Symrise_Logo.svg.png
EQS-News: Symrise sees successful start into the 2024 fiscal year
EQS-News: Symrise sees successful start into the 2024 fiscal year
EQS-News: Symrise AG again raises sales significantly in 2023 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23742/Symrise_Logo.svg.png
EQS-News: Symrise AG again raises sales significantly in 2023
EQS-News: Symrise AG again raises sales significantly in 2023
EQS-News: Press Release: Dr Jean-Yves Parisot assumes CEO position from Dr Heinz-Jürgen Bertram: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23742/Symrise_Logo.svg.png
EQS-News: Press Release: Dr Jean-Yves Parisot assumes CEO position from Dr Heinz-Jürgen Bertram
EQS-News: Press Release: Dr Jean-Yves Parisot assumes CEO position from Dr Heinz-Jürgen Bertram